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Aims: The aim of this study was to compare the effects of the selective M3 26 
muscarinic acetylcholine receptor antagonist Darifenacin, oral Hyoscine 27 
hydrobromide and Placebo on motion sickness induced by cross-coupled 28 
stimulation. 29 
Methods:  The effects of Darifenacin 10 mg or 20 mg, Hyoscine hydrobromide 30 
0.6 mg and Placebo were assessed in a randomised, double-blind, 4-way cross 31 
over trial of 16 healthy subjects. Motion sickness, skin conductance (a measure 32 
of sweating) and psychomotor cognitive function tests were investigated.  33 
Results:  Hyoscine hydrobromide produced significantly increased tolerance to 34 
motion versus Placebo (P<0.05 to P<0.01).  The motion protection effect of 35 
Darifenacin (10 or 20 mg) was approximately one third of that of Hyoscine 36 
hydrobromide, but was not significant versus Placebo.  Darifenacin and Hyoscine 37 
hydrobromide both significantly reduced skin conductance versus Placebo.  38 
Darifenacin produced either no effect or an enhanced effect on cognitive function 39 
in contrast to Hyoscine hydrobromide where there was significant impairment of 40 
psychomotor performance.    41 
Conclusion:  The results suggest that selective antagonism of the M3 receptor 42 
may not be important in the prevention of motion sickness.  However selective 43 
M3 antagonism does not impair cognitive function.  These observations may be 44 
important given that long term treatment with non-selective anti-muscarinic 45 




What is already known about this subject 48 
• Recent observational studies have demonstrated that long term usage of 49 
a non-selective anti-muscarinic antagonist is associated with an increased 50 
incidence of dementia.   51 
• Short term usage of Hyoscine hydrobromide for the treatment of motion 52 
sickness is known to be associated with drowsiness and other CNS side 53 
effects compatible with a direct effect on M1 & M2 receptor sub types.     54 
 55 
What this study adds 56 
• The study has shown that there are important differences in clinical effects 57 
produced by selective and non-selective antagonists on both motion 58 
sickness and cognitive function respectively.    59 
• The study demonstrates that selective M3 antagonists may enhance 60 
certain aspects of cognitive function and have a neutral effect on other 61 
domains.   62 
• The loss of an effect on motion sickness seen with the M3 selective anti-63 
muscarinic agent Darifenacin suggests that the M3 receptor subtype is not 64 
relevant in the prevention of motion sickness.      65 
 66 
 67 




Hyoscine hydrobromide, which is effective in the prophylaxis of motion 70 
sickness [1] shows similar binding affinities to all of the five known muscarinic 71 
acetylcholine receptor sub-types [2].  However, Hyoscine hydrobromide can 72 
produce a number of unwanted side effects including blurred vision, drowsiness 73 
and impaired psychomotor performance [3-5].  The development of selective 74 
muscarinic receptor antagonists with central actions leads to the possibility of 75 
enabling motion sickness protection with reduced side effects, provided that 76 
there is a functional separation between the roles of central muscarinic receptor 77 
subtypes.  Darifenacin is a selective muscarinic M3 receptor antagonist with 78 
good selectivity over atrial M2 and neuronal M1 receptors. Animal studies 79 
confirm central nervous system (CNS) penetration by Darifenacin following oral 80 
administration [6]. 81 
Darifenacin is approved for the treatment of urge urinary incontinence 82 
(UUI). Short-term studies have shown that commonly used non-selective anti-83 
muscarinic drugs such as Oxybutynin, have a detrimental effect on cognitive 84 
function [7]. 85 
We have compared the effects on motion sickness elicited by cross-86 
coupled stimulation of Darifenacin and of Hyoscine hydrobromide.  In addition, 87 
the effects on sweating measured by skin conductance (SC) and on a variety of 88 
aspects of psychomotor and cognitive function were evaluated.    89 




Study Design  92 
This was a randomised, Placebo controlled, double-blind, 4-way cross-93 
over study.  Over 4 study sessions the subjects were dosed with single oral 94 
doses of Darifenacin 10 mg, Darifenacin 20 mg, Hyoscine hydrobromide 0.6 mg, 95 
or Placebo. The order of administration of the 4 treatments was counterbalanced 96 
between subjects using a Latin Square design.  97 
Each study session had 2 stages. On the first the Motion Challenge 98 
described below was conducted 90 minutes after treatment administration. SC 99 
was also measured.  In order to avoid any problems of timings or effects and 100 
interactions of cognitive performance with motion sickness, the various CNS 101 
assessments including self-ratings and the performance of cognitive tests were 102 
conducted on a separate occasion at least 48 hrs following the motion sickness 103 
study.  The same dosing condition was administered. 104 
On the treatment days the drugs were administered with 200ml of water. 105 
Subjects were not required to fast overnight prior to study drug administration, 106 
however no heavy meals were allowed the night before and no food consumption 107 
was allowed one hour before drug administration. Subjects were required to not 108 
consume any alcohol for 24 hours, and to not smoke for one hour before 109 
treatment. 110 
The Darifenacin used in the study was an immediate release formulation 111 
administered orally in a capsule. For the purposes of this study two doses were 112 
prepared. Capsules contained either 10 mg or 20 mg of Darifenacin. Matching 113 
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Placebo and Hyoscine hydrobromide 0.6 mg capsules were also provided by 114 
Pfizer (Tadworth, United Kingdom). 115 
The wash-out period between treatments was 48 hours and deemed 116 
acceptable, given that the terminal half-life (t1/2) of Darifenacin and Hyoscine 117 
hydrobromide was 3.5-4.5 hours and 1-4.5 hours, respectively. 118 
The doses of these drugs were determined on the basis of previously published 119 
data. Hyoscine hydrobromide 0.6 mg is the standard dose for these types of 120 
clinical studies and the pharmacokinetic profile of this dose has been well studied 121 
[8]. 122 
The immediate-release (IR) formulation of Darifenacin (10 mg and 20 mg) 123 
showed similar effects on the bladder as the IR Oxybutynin [9], albeit produced 124 
less dry mouth. The pharmacokinetic properties of the IR and CR Darifenacin 125 
were similar with respect to tmax, albeit IR Darifenacin has an increased peak to 126 
trough ratio compared to CR [9-12]. 127 
 128 
Subjects 129 
Subjects were sixteen healthy male volunteers (mean 26.47 years; S.D. 130 
7.94, range 17-43 years) with intact vestibular function and not currently on other 131 
medications.  Prior to any study related procedures taking place, the subjects  132 
were fully informed of the procedures involved in this study and the risks of taking 133 
these drugs and their informed consent was obtained. Subjects were free to 134 
withdraw from the study any time. This study was approved by the Kent and 135 
Canterbury Hospital Ethics committee. During the consent and screening 136 
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process the subjects’ eligibility, medical history, medication use and fitness was 137 
thoroughly assessed by the investigators. Subjects were given sufficient time to 138 
read the ‘Information for Volunteers’ document and make an informed decision. 139 
All information provided by subjects was treated with confidentiality and integrity. 140 
All trial related activities were carried out in accordance with ICH GCP Guidelines 141 
and Declaration of Helsinki 1989. 142 
 143 
Procedures 144 
Prior to the start of the study, a familiarisation session was conducted with 145 
the motion challenge and SC assessment.  On another study session, the 146 
volunteers undertook the various CNS assessments on four repeated occasions 147 
to remove any training effects [13].  148 
On the study days involving the motion challenge, the study medication 149 
was administered 90 minutes prior to initiation of the challenge. On the cognitive 150 
function assessment days, the tasks were administered on arrival, prior to study 151 
treatment administration, and then again at 1.5, 3 and 4.5 hours after dosing.  152 
 153 
Motion Challenge 154 
Motion sickness was elicited by cross-coupled stimulation on a turntable, 155 
with subjects blindfolded.  The rotational velocity was incremented by 2 deg/sec  156 
every 30 sec, and a sequence of eight head movements of 45° ware completed 157 
every 30 sec [14].  Motion was stopped at moderate nausea, or 40 minutes, 158 
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whichever occurred sooner.  Subjects rated their degree of motion sickness on 159 
the following scale: 1 = no symptoms; 2 = Any symptoms however slight; 3 = Mild 160 
symptoms, e.g. stomach awareness but no nausea; 5 = Mild to moderate 161 
nausea; 6 = Moderate nausea but can continue; 7 = Moderate nausea, want to 162 
stop motion challenge [15].  At the end of motion, a sickness symptom checklist 163 
was administered for: Dizziness, Bodily warmth, Headache, Sweating, Stomach 164 
awareness, Increased salivation, Funny taste in mouth, Dry mouth, and Nausea 165 
(symptom scoring Nil=0, Mild=1, Moderate=2, Severe=3).  166 
 167 
Skin Conductance 168 
The skin conductance (SC) method employed was similar to that 169 
developed by Golding [14]. SC was recorded from 1st and 2nd finger palmar 170 
sites of the non-dominant hand, and from the left and right sides of the forehead 171 
close to the hairline approximately 2 to 4 cm above the eyebrows (supra-orbital 172 
ridge). Ag/AgCl electrodes were attached with double-sided self-adhesive 173 
stickers.  Total effective electrical skin contact area was 0.32 cm2 for the 2 finger 174 
electrodes and 0.32 cm2 for the 2 forehead electrodes.  The electrolyte used was 175 
0.05 M NaCl, in the range found in human sweat [16].  The electrolyte jelly was 176 
made up with carboxymethylcellulose as the gel agent: NaCl 0.3g plus low 177 
substitution carboxymethylcellulose 5g (BDH Ltd) plus water to 100g total [17].  178 
SC was measured using two constant current (10 µA) mains-isolated devices 179 
built in the laboratory.  Output was recorded in terms of DC-coupled (tonic) SC 180 
level (SCL) and as the amplified AC-coupled high pass signal (phasic) SC 181 
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responses (SCRs) (corner frequency 0.14 Hz). Following 12 bit A/D conversion 182 
at 5 Hz with anti-aliasing low pass filter above 2 Hz, the SCL and SCR signals 183 
were displayed online and stored on hard disk with automatic diskette back-up.  184 
SCR expressed as µmho RMS was subsequently analysed in the frequency 185 
band 0.005 - 0.48 Hz.   186 
 187 
Tests of CNS Function 188 
The volunteers were trained on the cognitive function assessments prior to the 189 
main study.  Each volunteer completed all the procedures four times during this 190 
training.  Subsequently on each study day in which cognitive function was 191 
assessed, the volunteers performed the tests one hour prior to dosing and at 1.5, 192 
3.5 and 4.5 hours afterwards.  The cognitive function tests took approximately 25 193 
minutes to complete. They were preceded by a mood and alertness 194 
questionnaire.  This questionnaire comprised sixteen 100 mm visual analogue 195 
scales which were combined as recommended by Bond and Lader [18] to derive 196 
3 factors: subjective alertness, subjective calmness and subjective contentment.  197 
The questionnaire has proven sensitive to a wide range of compounds [19-21].   198 
A selection of tasks from the Cognitive Drug Research (CDR) Computerised 199 
Cognitive Assessment System [22-25] was performed. The tests were 200 
administered in the following order: 201 
1. Word presentation 202 
2. Immediate word recall 203 
3. Simple reaction time 204 
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4. Digit vigilance task 205 
5. Choice reaction time 206 
6. Tracking 207 
7. Numeric working memory task 208 
8. DSST 209 
9. Delayed word recall 210 
10. Word recognition task 211 
11. Critical flicker fusion frequency (CFF) 212 
12. Body Sway: This was assessed using the Wright Ataxiameter 213 
 214 
On each testing session, parallel forms were administered, where 215 
appropriate (i.e. different lists of words different sequences of digits and different 216 
random sequences in tasks where the order of stimuli is randomised).  All tasks 217 
were computer controlled, the information being presented on high resolution 218 
monitors and then responses recorded via response modules containing two 219 
buttons, one marked "NO" and the other "YES" [22-25].   220 
 221 
Statistical analysis 222 
Following an initial scrutiny of the motion sickness data, checks were 223 
performed for appropriate symptom patterns, and for significance of order effects.  224 
Internal consistency checks were performed on times to motion endpoint 225 
between practice and Placebo sessions, and between individual symptom items. 226 
Analyses were carried out to examine the effects of systematic exclusions of 227 
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subject/treatment combinations where no nausea was reported at endpoint, or 228 
where the symptom pattern was highly suspect e.g. nausea but no stomach 229 
awareness, i.e. to exclude those data where motion was terminated at a nominal 230 
sickness rating of 7 but where the meaning of this rating was open to doubt.  231 
Two minutes blocks of SC data were extracted from the beginning of the 232 
motion challenge, i.e. well prior to the onset of initial symptoms of motion 233 
sickness, and two minutes blocks of SC data were taken at the end of the motion 234 
challenge, i.e. during the period of time of maximum motion sickness.  The 235 
differences between the first and last 2 minutes block of each finger and head SC 236 
dataset were addressed as a time factor in this analysis.  A preliminary analysis 237 
of variance (ANOVA) was performed on the log-transformed dataset to examine 238 
whether there was any significant run order effect.  No such run order effect was 239 
found, and therefore the analysis proceeded to address the treatment and time 240 
effects.  ANOVA was applied to partition the overall variation in the log-241 
transformed dataset, according to time, treatment, and the 2 way interaction 242 
between them.  Newman-Keuls Tests were applied to assess the differences 243 
between the individual treatments for each SC channel. In addition to ANOVAs, 244 
non-parametric tests (Wilcoxon) were used as appropriate. 245 
For the cognitive function data the statistical analysis was performed as 246 
follows; all data was adjusted for the pre-dosing scores on a study day to derive 247 
'difference from baseline scores'. 248 




Motion Challenge 251 
Visual scrutiny of times to sickness ratings revealed an appropriate pattern 252 
of symptoms, therefore an initial analysis of the data was made using ANOVAs 253 
and non-parametric (Wilcoxon) test which would be less sensitive to extreme 254 
responses than parametric analysis.  Times to sickness rating 7 were 255 
significantly longer for Hyoscine hydrobromide compared with Placebo (P=0.027 256 
2-tailed Wilcoxon Test), but Darifenacin at either dose was not significantly 257 
different from Placebo (Figure 1, Table 1). 258 
Data were identified for exclusion from the subsequent analysis by 259 
ANOVA by scrutinising for treatment/subject combinations which were unusual in 260 
terms of the expected associations between nausea and stomach awareness for 261 
symptom scores at motion endpoint, or typically where low nausea was recorded 262 
at motion endpoint (Supplementary Table 2).  In the latter event it was possible 263 
that a subject may have stopped for other reasons such as dizziness. 264 
A series of ANOVAs used these systematic exclusions of 265 
subject/treatment combinations. The majority of Hyoscine hydrobromide versus 266 
Placebo comparisons were significant (21/32 comparisons at P<0.05; 15/32 267 
comparisons at P<0.001), whereas none were significant for Darifenacin (10 or 268 
20 mg) versus Placebo. 269 
On average Hyoscine hydrobromide 0.6 mg produced an increased 270 
motion tolerance over Placebo of around 3 min, whereas Darifenacin 10 or 271 
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20 mg produced an increased motion tolerance over Placebo averaging around 1 272 
min (Figure 1). 273 
 274 
Symptom scores at motion endpoint 275 
ANOVA of symptom scores at motion endpoint revealed significant treatment 276 
effects on dry mouth, salivation and bodily warmth. Dry mouth was significantly 277 
higher for Hyoscine hydrobromide (P<0.05) and for Darifenacin (10 mg P<0.05, 278 
20 mg P<0.001), versus Placebo.  Salivation and bodily warmth were both 279 
significantly lower (P<0.05) with Darifenacin 20 mg versus Placebo.  Symptom 280 
scores at motion endpoint are presented in Figure 2. 281 
 282 
Skin Conductance 283 
An example SC recording is shown in Figure 3.  Figure 4 presents example 284 
palmar phasic SC records for the four treatment conditions, prior to motion 285 
sickness.  Figure 5 presents the mean SC activity for the initial 2 min sample pre-286 
motion sickness and the final 2 min sample during motion sickness 287 
For finger SC, the mean log signal power for the last 2 minutes block was 288 
larger, to a small but significant extent, than that for the first 2 minutes 289 
(F(1,15)=4.922, p<0.05). There was also a significant treatment effect 290 
(F(3,15)=8.099, p<0.01).  All three drug treatments gave significantly lower mean 291 
log signal power than did Placebo, but the three drug treatments were not 292 
significantly different one from another. The overall difference between 10 mg 293 
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Darifenacin and Placebo, and  between 0.6 mg Hyoscine hydrobromide and 294 
Placebo were both significant at p<0.05. The overall difference between Placebo 295 
and 20 mg Darifenacin was significant at p<0.01.  Specific comparisons of each 296 
drug treatment versus Placebo were performed for equivalent time periods, in 297 
order to further isolate effects.  These are shown in Figure 5. 298 
For forehead SC, the mean log signal power for the last 2 minutes block 299 
was significantly greater than that for the first 2 minutes (F(1,33)=17.999, 300 
p<0.001).  The treatment effect was marginal (F(3,15)=2.951, p=0.06).  The 301 
overall difference between Placebo and 20 mg Darifenacin showed a significantly 302 
lower mean log power for Darifenacin, at p<0.05.  Specific comparisons of each 303 
drug treatment versus Placebo were performed for equivalent time periods, in 304 
order to further isolate effects.  These are shown in Figure 5. 305 
 306 
Cognitive Function Testing  307 
Oral Hyoscine hydrobromide significantly reduced the accuracy of choice 308 
reaction time performance and increased body sway.  A number of trends for 309 
impairment were detected, particularly at 4.5h post dosing where vigilance 310 
accuracy was decreased, tracking error increased and performance on the digit 311 
symbol substitution tests and critical flicker fusion tests impaired.  When 312 
Hyoscine hydrobromide was compared directly to Darifenacin, performance with 313 
Hyoscine hydrobromide was consistently found to be inferior to that with one or 314 
both Darifenacin doses.  At 1.5h post dosing, significant impairments with 315 
Hyoscine hydrobromide were seen on simple reaction time, body sway, vigilance 316 
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accuracy, DSST performance, CCF tracking, working memory sensitivity and 317 
subjective alertness. The only clearly negative effect of Darifenacin was for both 318 
doses to significantly increase body sway 4.5h post-dosing. 319 
 320 
Discussion  321 
The aim of this experiment was to investigate the effects of Darifenacin 322 
and Hyoscine hydrobromide on motion sickness, sweating and psychomotor 323 
performance.  At the dose used, Hyoscine hydrobromide produced a significantly 324 
increased motion tolerance over Placebo of around 3 min, whereas Darifenacin 325 
10 or 20 mg non-significantly increased motion tolerance over Placebo by around 326 
1 min.  To place these motion sickness protection values in context, a previous 327 
trial [8] using comparable methods but different subjects [26] demonstrated that 328 
Hyoscine hydrobromide 0.6 mg gave a significantly increased tolerance over 329 
Placebo of 2.9 min.  Thus the results for Hyoscine hydrobromide in the present 330 
trial (3 min) were consistent with what might be expected from other evidence 331 
using this method. 332 
   Any putative anti-motion sickness effect for Darifenacin in the dose range 333 
here would be small by comparison to Hyoscine hydrobromide 0.6 mg.  Given 334 
the negative evidence for the role of M1 or M2 receptors [27] and positive 335 
evidence (Zamifenacin) for a role for M3/m5 receptors in mediating anti-motion 336 
sickness actions [8], the  negative results of this experiment for M3 point to a 337 
more important role for the m5 receptor. A role for the M4 autoreceptor in motion 338 
sickness is also possible.    339 
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Darifenacin significantly reduced ongoing SC activity at the fingers before 340 
motion sickness, as did Hyoscine hydrobromide.  The Darifenacin induced 341 
reduction of SC activity, across the dose range employed, was similar in 342 
magnitude to that produced by Hyoscine hydrobromide.  Although the higher 343 
dose of Darifenacin appeared to give the larger effect, a dose response effect 344 
between 10 mg and 20 mg of Darifenacin could not be demonstrated at a level of 345 
statistical significance.  A broadly similar pattern of effects was observed at the 346 
finger sites during motion sickness. 347 
Forehead sweating at baseline was minimal, which unsurprisingly was not 348 
significantly further reduced by the drugs.  SC activity increased significantly 349 
during motion sickness, particularly at the forehead recording site, a finding 350 
consistent with previous work [14].  Darifenacin and Hyoscine hydrobromide 351 
significantly reduced this activity.  A dose response effect between 10 mg and 352 
20 mg of Darifenacin could not be demonstrated at a level of statistical 353 
significance, although the higher dose of Darifenacin appeared to give the larger 354 
effect by comparison with Placebo. 355 
The reduction of forehead sweating during motion sickness observed with 356 
Darifenacin or Hyoscine hydrobromide was probably due to a direct drug action 357 
on sweating.  The possibility of drug action on SC activity via CNS effects cannot 358 
be ruled out entirely since the drugs were given systemically.  The muscarinic 359 
postganglionic innervation of the sweat gland is thought to be of the M3 type [28], 360 
suggesting that the action on SC activity of either drug is by virtue of their actions 361 
at such receptors.   362 
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Subjective symptoms of dry mouth were significantly higher for Hyoscine 363 
hydrobromide and for Darifenacin versus Placebo.  Salivation and bodily warmth 364 
were both significantly lower with Darifenacin 20 mg versus Placebo.  Such 365 
effects are consistent with the well-known profile of action of anti-muscarinics on 366 
secretory glands and are probably occurring at the M3 receptor [28].  This pattern 367 
of response would also be consistent with the significant sweating reduction 368 
noted above for Hyoscine hydrobromide and Darifenacin on the SC measures. 369 
When Hyoscine hydrobromide was compared directly to Darifenacin, 370 
performance with Hyoscine hydrobromide was consistently found to be inferior to 371 
that with one or both of the Darifenacin doses.  At 1.5h post dosing, significant 372 
impairments with Hyoscine hydrobromide were seen on simple reaction time, 373 
body sway, vigilance accuracy, DSST performance and subjective alertness.  At 374 
4.5h, similar significant effects were seen on vigilance accuracy, DSST 375 
performance, CFF tracking, working memory sensitivity and subjective alertness. 376 
Darifenacin was largely free of impairing effects on cognition, in fact 377 
performance appeared to be improved by the drug.  Both doses significantly 378 
improved simple reaction time and the low dose significantly improved working 379 
memory sensitivity, subjective alertness and subjective contentment.  The high 380 
dose showed improved choice reaction time while the low dose showed a similar 381 
trend for improving vigilance reaction time.  The only clearly negative effect of 382 
Darifenacin was for both doses to significantly increase body sway 4.5h post-383 
dosing.  The absence of an increase in tracking error with Darifenacin strongly 384 
suggests that this was not an effect on co-ordination and thus the basis for this 385 
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effect on postural stability is unclear.  The magnitude of the effect is in the region 386 
of that produced by 2-3 units of alcohol and thus is clearly not a marked effect.  387 
These findings consistently demonstrate that subjects will be better off in terms of 388 
their ability to concentrate and conduct skilled activities when taking Darifenacin 389 
than when taking Hyoscine hydrobromide at the doses used in this study. 390 
Overall the present study has demonstrated that when the volunteers 391 
received Hyoscine hydrobromide, their general ability to maintain attention and 392 
concentrate was inferior to that when they were given Darifenacin.  This is in part 393 
due to the impairments produced by Hyoscine hydrobromide, but exaggerated in 394 
some cases by unexpected improvements seen with Darifenacin.  Nonetheless, 395 
the outcome is that volunteers would clearly be in a better position to drive and 396 
conduct activities requiring high levels of concentration and co-ordination when 397 
taking Darifenacin than while taking Hyoscine hydrobromide. 398 
Hyoscine hydrobromide produced significant decrements in psychomotor 399 
performance which were similar to previous published data [4].  Darifenacin 400 
produced little or no impairment at either dose or even an enhanced effect on 401 
certain parameters, suggesting that such impairments produced by Hyoscine 402 
hydrobromide are not mediated by M3 receptors.   403 
Muscarinic receptors expressed in the brain modulate a multitude of 404 
signaling pathways involved in critical functions including attention, memory and 405 
learning.  Quantitative analysis studies have identified the five subtypes with 406 
varying expression levels throughout the brain.  M1, M2 and M4 are the dominant 407 
subtypes, while M3 and M5 are found at lower levels [29].  408 
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M1 receptors are of particular interest in the cortical areas and the 409 
hippocampus [30] as it has been shown that their inhibition leads to impaired 410 
spatial memory [29].  Molecular manipulations of the m1 gene have been shown 411 
to cause cognitive deficits [31], whereas the administration of known agonists of 412 
the M1 receptor subtype in human subjects with Alzheimer’s disease and 413 
schizophrenia improved memory and learning [32, 33].  These findings indicate 414 
that M1 receptor antagonism causes adverse reactions in the CNS [34].   415 
Delivery of drugs to the CNS depends on molecular characteristics; these 416 
include molecular size, polarity and lipophilicity (Supplementary Table 3) [7, 8, 417 
35-38].  The physicochemical properties of Oxybutynin and Hyoscine 418 
hydrobromide grant these molecules high propensity to penetrate the blood-brain 419 
barrier freely, thus high concentrations can reach the central M1 receptors [39].  420 
The affinity of anti-muscarinics for specific receptors is an important factor 421 
contributing to CNS effects. Oxybutynin has been shown to have similar 422 
selectivity for M1 and M3 receptors (pKi 8.7 and 8.9, respectively) and is 423 
considered non-selective [30].  Short term studies have demonstrated 424 
impairment of cognitive function after Oxybutynin therapy [40].  A recent 425 
observational study has shown that chronic usage of Oxybutynin in patients with 426 
UUI is associated with a significant increase in the incidence of dementia [41].   427 
The positive cognitive function data shown in this study should be confirmed in 428 
long-term studies in patients with UUI treated with Darifencin.  It would seem 429 
axiomatic to avoid chronic usage of anti-muscarinic agents that result in adverse 430 
effects on cognitive function which may not be reversible and lead to dementia.  431 
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We conclude that the muscarinic M3 receptor is unlikely to be the most important 432 
receptor mediating the anti-motion sickness actions of Hyoscine hydrobromide.  433 
This result, in conjunction with other data, indicates a more important role for the 434 
m5 receptor in motion sickness.  In addition, this study suggests that selective 435 
antagonism of the M3 receptor does not produce a deleterious effect on cognitive 436 
function.  This observation may be important when considering selection of a 437 
suitable anti-muscarinic agent for long term treatment of chronic conditions such 438 
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Figure legends 566 
 567 
Figure 1. – Mean times to sickness rating 7 "moderate nausea & wish to stop" 568 
(motion endpoint) for the three active treatments and Placebo, repeated on n=15 569 
subjects completing all treatments. Motion sickness was elicited by cross-570 
coupled stimulation on a turntable. The mean times shown are representative of 571 
the range of results produced by exclusions on the basis of statistical symptom 572 
pattern tests, or on the basis of contradictions between nominal sickness rating 573 
and recorded symptoms such as nausea and stomach awareness at motion 574 
endpoint. The majority of Hyoscine hydrobromide (HBr) 0.6 mg versus Placebo 575 
comparisons were significant (P<0.05 to P<0.001), whereas none were 576 
significant for Darifenacin (10 or 20 mg) versus Placebo. 577 
 578 
Figure 2. – Mean Symptom scores (0=nil, 1=mild, 2=moderate, 3=severe) are 579 
shown at the motion endpoint of sickness rating 7, for n=15 subjects completing 580 
all treatments. The most consistent effect was that Darifenacin and Hyoscine 581 
hydrobromide (HBr) increased subjective dry mouth. 582 
 583 
Figure 3. – Skin conductance recordings at forehead and finger palmar sites 584 
during motion sickness challenge show finger palmar site being active throughout 585 
the test, showing non-specific response, whereas the forehead site is showing 586 
rapid increase at the onset of moderate nausea, as reflected in the Increase in 587 




Figure 4. – Palmar finger skin conductance activity plots for one subject over the 590 
four treatments, prior to the onset of motion sickness. All traces are of 4 minutes 591 
duration starting at the beginning of the motion challenge, time zero. Note that 592 
oral Hyoscine hydrobromide (HBr) 0.6 mg and oral Darifenacin 10 mg and 20 593 
mg, all reduce skin conductance activity by comparison with Placebo. The effect 594 
was most marked for the high Darifenacin dose. 595 
 596 
Figure 5. - Mean phasic skin conductance activity, at the palmar finger and 597 
forehead sites, is plotted for the four treatment conditions. The mean phasic skin 598 
conductance activity is based on two minute samples at the beginning of the 599 
motion challenge prior to motion sickness, and two minute samples at the end of 600 
the motion challenge during maximum motion sickness. Darifenacin and 601 
Hyoscine hydrobromide (HBr) significantly reduced phasic skin conductance 602 
activity compared with Placebo (for example see Figure 3). At the forehead 603 
recording site, the rise in skin conductance activity over time represented motion 604 
sickness induced sweating (for example see forehead signal in Figure 4). 605 
 606 
Supplementary Figures 1-3. – Motion sickness test on rotating chair showing 607 












 Mean Standard Deviation N 
Practice 14.63 5.22 15 




20.70 7.70 15 
Darifenacin 
10mg 18.93 7.46 15 
Darifenacin 
20mg 18.90 7.31 15 
 
 
Supplementary Table 1. Psychomotor and cognitive performance tests: mean (SD) pre- and 
post-drug (control: Placebo; Dar10: Darifenacin 10 mg; Dar20 Darifenacin 20 mg; Hyoscine: 
Hyoscine hydrobromide 0.6 mg), oral drug was given at time zero. 
Test 
(n = 15) 
Drug Type Time (Hours) 
 
-1 1.5 3 4.5 
Simple Reaction 
Time (msec) 
Control 232.4 (20.27) 262.7 (52.24) 262.7 (60.70) 259.9 (49.82) 
Dar10 250.3 (34.23) 255.1 (30.28) 268.2 (41.83) 260.2 (43.25) 
Dar20 243.1 (45.60) 249.5 (37.98) 252.5 (36.48) 261.8 (47.97) 




Control 98.96 (2.03) 98.96 (2.50) 98.37 (1.96) 98.37 (1.56) 
Dar10 98.08 (2.50) 99.11 (1.84) 96.89 (3.83) 97.93 (2.58) 
Dar20 97.78 (3.03) 98.07 (4.59) 98.07 (2.36) 97.78 (3.36) 
Hyoscine 99.11 (2.02) 97.04 (3.53) 97.63 (2.58) 96.74 (3.01) 
Digit Vigilance – 
Speed (msec) 
Control 404.2 (35.70) 415.6 (38.53)   415.4 (39.42)  418.6 (41.42) 
Dar10 420.8 (45.77) 416.0 (51.29) 426.3 (49.38) 423.8 (40.72) 
Dar20 408.1 (39.46)     424.3 (47.64)      420.8 (46.98)    424.0 (47.25)       




Control 0.733 (0.96)       1.000 (1.41) 0.867 (1.06) 0.533 (1.06) 
Dar10 0.933 (1.10) 0.267 (0.59) 0.333 (0.62) 0.333 (0.82) 
Dar20 0.933 (1.28)       0.733 (0.80) 1.067 (2.02) 0.600 (1.35) 




Control 94.67 (6.79) 96.67 (2.90) 96.00 (4.00) 93.87 (6.35) 
Dar10 95.47 (4.98) 95.33 (5.88) 96.00 (2.51) 94.53 (3.96) 
Dar20 96.13 (3.96) 96.13 (5.37) 93.33 (5.33) 95.33 (5.43) 
Hyoscine 97.20 (1.97) 94.27 (6.36) 95.33 (5.12)      92.80 (8.02) 
Choice Reaction 
Time: Speed 
(msec)   
Control 403.7 (57.84) 415.0 (62.68) 414.4 (72.36) 414.3 (76.37) 
Dar10 413.0 (70.27) 406.7 (60.58) 425.3 (74.52) 417.1 (61.98) 
Dar20 414.2 (49.98) 408.3 (57.56) 403.1 (50.93) 406.7 (69.04) 
Hyoscine 414.2 (64.64) 414.2 (60.60) 420.2 (62.53) 415.9 (58.89)  
Tracking Mean 
Error (mm) 
Control 22.93 (3.21)       23.35 (3.73)       23.10 (2.90)       23.68 (3.83)       
Dar10 23.06 (2.81) 23.59 (4.37)  22.86 (3.41) 23.47 (4.64) 
Dar20 23.41 (3.42) 23.11 (3.30) 23.33 (3.37) 23.09 (3.56) 




Control 0.894 (0.10) 0.867 (0.13) 0.857 (0.15) 0.842 (0.14) 
Dar10 0.883 (0.07) 0.889 (0.09) 0.911 (0.06) 0.904 (0.08) 
Dar20 0.908 (0.07)      0.888 (0.09) 0.878 (0.10) 0.856 (0.13) 
Hyoscine 0.906 (0.07)      0.880 (0.10)      0.876 (0.13)      0.846 (0.14) 
Numeric Working 
Memory – Speed 
Control 568.2 (81.95)       565.9 (87.70)       559.2 (73.39)       542.9 (70.62)  
Dar10 556.7 (75.43)       558.8 (71.00)       550.7 (78.99)       553.6 (77.52)  
Dar20 565.0 (62.73)       559.2 (72.42)       548.8 (62.06)       553.8 (70.17)  




Control 0.674 (0.19) 0.561 (0.20) 0.533 (0.23) 0.504 (0.31) 
Dar10 0.678 (0.18) 0.560 (0.20) 0.612 (0.18) 0.533 (0.13) 
Dar20 0.591 (0.18) 0.532 (0.22) 0.523 (0.23)        0.485 (0.22) 
Hyoscine 0.608 (0.19)      0.528 (0.27)   0.538 (0.19)      0.431 (0.36)     
Word Recognition 
– Speed (msec) 
Control 655.5 (133.7) 677.0 (118.1) 701.1 (136.9) 642.7 (111.2) 
Dar10 670.0 (90.26)       668.9 (118.6) 704.3 (107.9) 690.5 (144.8) 
Dar20 653.3 (79.29) 661.4 (111.7) 676.8 (115.4) 720.3 (150.6) 
Hyoscine 711.5 (93.38) 649.7 (113.7) 709.2 (149.5)      682.2 (157.3) 
Critical Flicker 
Fusion (HE) 
Control 41.07 (4.11) 41.57 (4.20)      41.67 (3.75) 42.53 (3.20) 
Dar10 41.73 (3.04)       41.87 (3.54)       41.87 (4.29)      41.60 (3.23) 
Dar20 40.67 (4.00)       42.07 (3.58)       41.93 (4.25)       42.53 (3.76)  






(n = 15) Drug Type 
Time (Hours) 
 
-1 1.5 3 4.5 
Body Sway Control 21.33 (2.81) 17.80 (12.04) 19.27 (3.17) 16.33 (9.93) 
Dar10 17.40 (9.13) 15.67 (7.87) 17.80 (11.52) 19.40 (12.13) 
Dar20 15.33 (6.33)       15.93 (7.67) 16.80 (11.09) 18.07 (12.27) 
Hyoscine 16.13 (9.55) 20.60 (12.98) 20.53 (19.18)       20.40 (15.06)       
Digit Symbol Test 
(n correct) 
Control 76.47 (13.49) 76.93 (14.38)      75.80 (14.56) 77.20 (14.23) 
Dar10 73.87 (13.50) 76.13 (13.05) 75.40 (13.87) 76.07 (12.75) 
Dar20 74.80 (11.83) 75.80 (12.32)       75.87 (12.84)       75.93 (12.12) 




Control 54.66 (16.80) 45.77 (14.34)  45.55 (14.46)  44.66 (13.89) 
Dar10 48.88 (14.18)  48.11 (13.78) 45.89 (11.93) 45.22 (13.23) 
Dar20 50.11 (9.22)) 46.33 (12.79) 46.33 (11.48)  42.55 (11.56) 
Hyoscine 48.44 (15.10) 43.77 (17.87) 48.00 (12.07) 41.44 (10.78) 
Delayed Word 
Recall Accuracy % 
Control 39.77 (19.62)       27.00 (11.87)       25.44 (15.07)       22.44 (13.60) 
Dar10 34.22 (12.05)       26.88 (11.85)       21.33 (12.65)       22.00 (8.34) 
Dar20 32.00 (13.20)       29.55 (13.43)       21.11 (10.42)       19.77 (11.02) 
Hyoscine 30.55 (11.54) 23.44 (15.59)    20.66 (12.10) 20.44 (14.41) 
Alertness Control 65.63 (11.2) 60.69 (13.00) 54.87 (15.42) 57.39 (16.51) 
Dar10 58.21 (17.76)       65.47 (15.73) 59.06 (15.70) 58.03 (17.21) 
Dar20 62.13 (18.69)       60.12 (12.93) 59.48 (16.45) 57.54 (14.92)  
Hyoscine 59.55 (13.54)       51.57 (17.47)       49.82 (17.16)       52.51 (15.21)  
Contentment Control 76.57 (13.78)      76.56 (14.01)       71.51 (12.85)       74.29 (17.92) 
Dar10 75.92 (12.83) 75.73 (14.06)       78.44 (12.70) 76.00 (13.67) 
Dar20 73.05 (16.03)       75.51 (14.80) 70.87 (16.07) 71.53 (14.38)  
Hyoscine 76.04 (9.90) 74.36 (12.59) 73.77 (14.13)       73.99 (13.49)  
Calmness Control 70.90(13.66) 70.27 (11.81)       71.83 (10.63)       73.67 (11.97 
Dar10 73.07 (11.01)       75.33 (11.91)       76.30 (12.60)       74.90 (11.89)  
Dar20 72.97 (14.96) 73.47 (11.92)       72.87 (13.43) 67.00 (17.45) 



























(n = 15) 
Drug Type Time (Hours) 
 
DB1 DB3 DB4 
Alertness Control -4.940 (11.46) -10.75 (12.16) -8.240 (14.03) 
Dar10 7.253 (16.58) 0.847 (13.22) -0.187 (14.79) 
Dar20 -2.007 (16.43) -2.647 (16.74) -4.587 (18.16) 
Hyoscine -7.973 (13.19) -9.727 (14.16) -7.033 (15.79) 
Calmness Control -0.633 (11.15) 0.933 (13.85) 2.767 (11.33) 
Dar10 2.267 (17.33) 3.233 (13.05) 1.833 (15.61) 
Dar20 0.500 (8.045) -0.100 (16.57) -5.967 (21.78) 




Control 0.786 (2.01) 0.600 (2.23) 1.467 (2.20) 
Dar10 0.133 (1.31) 0.133 (2.07) -0.133 (1.18) 
Dar20 1.400 (3.57) 1.267 (2.15) 1.867 (2.42) 
Hyoscine -0.067 (1.71) 0.533 (1.51) 0.0667 (2.74) 
Contentment Control -0.013 (6.05) -5.067 (8.77) -2.280 (12.51) 
Dar10 -0.187 (10.03) 2.520 (7.55) 0.08 (13.20) 
Dar20 2.453 (8.98) -2.187 (11.61) -1.520 (13.00) 
Hyoscine -1.680 (6.38) -2.267 (8.53) -2.053 (5.85) 
Choice 
reaction time 
Control 11.34 (22.56) 10.73 (28.21) 10.59 (33.68) 
Dar10 -6.245 (24.56) 12.33 (24.19) 4.140 (25.89) 
Dar20 -5.913 (27.41) -11.12 (19.58) -7.557 (35.81) 
Hyoscine 0.054 (42.01) 6.024 (41.38) 1.723 (32.83) 
Choice 
reaction time 
– Accuracy  
Control 2.000 (7.64) 1.333 (6.66) -0.800 (6.67) 
Dar10 -0.133 (3.50) 0.533 (3.66) -0.933 (4.13) 
Dar20 0 (3.67)      -2.800 (4.88) -0.800 (3.10) 




Control -12.78 (20.30) -14.33 (18.12) -17.33 (25.58) 
Dar10 -7.335 (14.92) -12.89 (14.79) -12.22 (10.37) 
Dar20 -2.443 (8.47) -10.89 (13.76) -12.22 (21.11) 
Hyoscine -7.112 (16.43) -9.890 (14.40) -10.11 (15.18) 
DRECRT Control 21.50 (65.89) 45.64 (69.62) -12.78 (80.86) 
Dar10 -1.099 (69.45) 34.33 (64.56) 20.49 (89.40) 
Dar20 8.069 (75.10) 23.44 (113.5) 66.94 (119.3) 





Control -0.113 (0.20) -0.141 (0.17) -0.170 (0.25) 
Dar10 -0.118 (0.20) -0.065 (0.22) -0.145 (0.21) 
Dar20 -0.059 (0.18) -0.068 (0.20) -0.106 (0.17) 
Hyoscine -0.08 (0.27) -0.069 (0.25) -0.177 (0.34) 
Digit symbol 
test 
Control 0.467 (2.48) -0.667 (4.29) 0.733 (4.37)  
Dar10 2.267 (5.47) 1.533 (5.49) 2.200 (5.74) 
Dar20 1.000 (3.76) 1.067 (5.50) 1.133 (4.37) 
Hyoscine -0.267 (3.96) 0.133 (4.05) -1.533 (5.08) 
Immediate 
word recall – 
Accuracy  
Control -8.889 (15.28) -9.111 (13.06) -9.999 (14.73) 
Dar10 -0.777 (11.39) -2.999 (10.77) -3.665 (12.25) 
Dar20 -3.777 (11.35) -3.777 (8.273) -7.554 (15.42) 
Hyoscine -4.667 (11.36) -0.444 (10.77) -7.001 (14.90) 
MSRT Control -2.309 (37.73) -8.949 (35.36) -25.24 (42.49) 
Dar10 2.184 (46.93) -5.934 (35.26) -3.073 (38.05) 
Dar20 -5.866 (39.78) -16.24 (32.73)) -11.24 (50.42) 
Hyoscine 1.640 (34.32) -11.83 (44.15) 4.759 (70.59) 
MSSI Control -0.027 (0.07) -0.037 (0.08) -0.053(0.09) 
Dar10 0.0056 (0.09) 0.0282 (0.07) 0.0211 (0.08) 
Dar20 -0.02 (0.07) -0.03 (0.08) -0.052 (0.13) 




Control 30.31 (37.35) 30.34 (46.08) 27.55 (32.47) 
Dar10 4.845 (21.33) 17.87 (17.91) 9.953 (28.77) 
Dar20 6.379 (20.56) 9.335 (28.18) 18.67 (26.98) 
Hyoscine 25.65 (16.81) 26.08 (26.74) 20.07 (24.04) 
 Test 
(n = 15) 
Drug Type Time (Hours) 
 
DB1 DB3 DB4 
Body sway Control -3.533 (8.43) -2.067 (8.79) -5.000 (5.79) 
Dar10 -1.733 (8.16) 0.400 (7.81) 2.000 (6.50) 
Dar20 0.600 (4.718) 1.467 (10.08) 2.733 (10.24) 
Hyoscine 4.467 (6.37) 4.400 (13.47) 4.267 (10.63) 
Tracking 
mean error 
Control 0.425 (2.02) 0.336 (1.30) 0.756 (2.01) 
Dar10 0.532 (3.18) -0.199 (1.99) 0.414 (3.44) 
Dar20 -0.293 (2.25) -0.08 (1.93) -0.314 (2.11) 
Hyoscine 1.328 (2.27) 1.428 (1.71) 3.230 (7.46) 
Digit vigilance 
– Accuracy 
Control 0 (3.46)     -0.592 (2.84) -0.591 (2.96) 
Dar10 1.036 (3.01) -1.185 (4.19) -0.148 (2.84) 
Dar20 0.296 (3.24) 0.296 (3.35) -67E-5 (3.85) 
Hyoscine -2.072 (4.07) -1.481 (2.74) -2.370 (2.72) 
Digit vigilance 
– False alarm 
Control 0.267 (1.58) 0.133 (0.99) -0.200 (1.42) 
Dar10 -0.667 (0.82) -0.600 (1.24) -0.600 (0.83) 
Dar20 -0.200 (1.32) 0.133 (2.39) -0.333 (2.02) 




Control 11.44 (20.35) 11.25 (28.34) 14.40(33.23) 
Dar10 -4.799 (26.46) 5.453 (29.67) 2.974(26.75) 
Dar20 16.13 (28.00) 12.71 (19.39) 15.91(27.44) 














Supplementary Table 2.  Times (Minutes) To A Sickness Rating of 7 
 
 
Subject Practice Placebo Hyoscine Darifenacin 10mg 
Darifenacin 
20mg 
1 14.5 15.5 18.0 14.0 17.0 
2 15.5 14.5 18.0 17.5 17.0 
3 21.0 27.0 30.0 20.5 23.5 
4 19.5 20.0 25.0 20.0 21.5 
5 9.0 21.5 8.5 19.5 21.0 
6 13.0 17.0 18.0 19.0 15.5 
7 10.5 12.5 13.5 11.0 12.0 
8 13.5 15.0 18.0 16.0 14.0 
9 25.0 26.5 N/A N/A N/A 
10 26.5 31.5 29.5 41.0 39.0 
11 10.5 14.5 13.0 12.5 13.0 
12 7.0 15.5 18.5 14.0 18.0 
13 14.0 18.0 22.5 21.5 15.0 
14 20.5 25.5 39.0 28.0 29.5 
15 11.5 14.5 22.0 15.0 15.5 
16 13.0 12.0 17.0 14.5 12.0 
 
 
Subject 4 was excluded in the Darifenacin 20mg session. 
Subject 5 was excluded in the Hyoscine session. 
Subject 9 did not complete the study. 
Subject 12 was excluded in the Darifenacin 10mg session. 
Subject 14 was excluded in the Darifenacin 10mg session. 
 
These subjects were excluded based on reports of no nausea at the motion endpoint. 
Supplementary Table 3:  Molecular and pharmacological properties of antimuscarinic compounds 
Antagonist Darifenacin Oxybutynin Solifenacin Tolterodine Hyoscine Zamifenacin 
Physicochemical 
properties [30] 






(hydrobromide -  
384.27) 
415.533 
(fumerate -  
531.605) 
Polarity Positive Neutral Neutral Positive Neutral Neutral 





selective & P-gp 
substrate) 
High High Moderate/High High N/A 
Bioavailability 
(%) 15-19 6 90 77 10-50 N/A 
Protein binding 




7-20 13 45-68 2-10 4.5 N/A 
Metabolite None Desethyl-oxybutynin None 5-HMT None N/A 
P-glycoprotein 
substrate Yes No No No No N/A 
Receptor subtype 
selectivity (pKi) 
M1 8.2 (0.04) [35] 8.7 (0.04) [35] 7.6 8.8 (0.01) [35] 8.95 (0.31) [39] 7.2 [37] 
M2 7.4 (0.10) [35] 7.8 (0.10) [35] 7.1 8.0 (0.10) [35] 8.68 (0.08) [39] 7.9 [37] 
M3 9.1 (0.10) [35] 8.9 (0.10) [35] 7.7 8.5 (0.10) [35] 9.41 (0.07) [39] 6.9 [37] 
M4 7.3 (0.10) [35] 8.0 (0.04) [35] 6.8 8.0 (0.04) [35] 9.47 (0.06) [39] 7.3 [38] 
M5 8.0 (0.10) [35] 7.4 (0.03) [35] 7.2 7.4 (0.03) [35] N/A N/A 
Receptor affinity 
ratio [35] 
M3:M1 9.3** 1.5* 2.5 0.6* N/A N/A 
M3:M2 59.2** 12.3** N/A 3.6** N/A N/A 













Motion sickness effect Mild negative[7] N/A N/A N/A High positive[8] Moderate positive [8] 
 
N/A – not available 
a Ki ratios were compared by ANOVA. *p<0.05, **p<0.001 [35] 
b drug administered as oxybutynin chloride 
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